Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)
Not Applicable
Completed
- Conditions
- classical Hodgkin's lymphoma
- Registration Number
- JPRN-jRCT1080224013
- Lead Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
All patients with relapsed or refractory classical Hodgkin's lymphoma to whom OPDIVO was administered
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Safety items : Occurrence status of adverse events (including adverse drug reactions)
- Secondary Outcome Measures
Name Time Method efficacy<br>Efficacy items : Comprehensive improvement (the best antitumor efficacy by 6 and 12 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)